摘要
膜性肾病是成人肾病综合征的常见原因之一。Ⅰ型抗CD20单克隆抗体利妥昔单抗是治疗膜性肾病的有效药物,然而其使用后的完全或部分缓解率(随访至24个月)仅为60%。奥妥珠单抗是经糖基化改造的Ⅱ型人源化抗CD20单克隆抗体,与利妥昔单抗相比,它能引起更加严重的B淋巴细胞耗竭,因此其在治疗某些血液系统恶性肿瘤方面表现出更好的效果。在狼疮肾炎、肾移植等的治疗中奥妥珠单抗也展现出了良好的治疗效果,基于此一些中心已在膜性肾病中尝试使用奥妥珠单抗,本文就奥妥珠单抗在膜性肾病中的应用做一综述。
Membranous nephropathy(MN)is a common cause of adult nephrotic syndrome.Rituximab,a typeⅠanti-CD20 monoclonal antibody,is an effective treatment of MN.However,its response rate is merely 60%during a follow-up period of up to 24 months.Obinutuzumab is a typeⅡhumanized anti-CD20 monoclonal antibody modified by glycosylation.As compared with rituximab,it can cause a more severe depletion of B lymphocyte so as to demonstrate a better efficacy for some hematological malignancies.Currently obinutuzumab is applied for lupus nephritis and kidney transplantation.Based upon its definite efficacy,some centers have promoted using obinutuzumab for MN.This review summarized the clinical application of obinutuzumab.
作者
林小靖
孙静
相里浩怡
杜玄一
Lin Xiao-jing;Sun Jing;Xiangli Hao-yi;Du Xuan-yi(Department of Nephrology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)
出处
《临床肾脏病杂志》
2024年第1期61-64,共4页
Journal Of Clinical Nephrology
关键词
膜性肾病
磷脂酶A2受体
肾病综合征
Membranous nephropathy
Phospholipase A2 receptors
Nephrotic syndrome
